PROPANC BIOPHARMA, INC. Debt Conversion, Original Debt, Amount
PROPANC BIOPHARMA, INC. (PPCB) had Debt Conversion, Original Debt, Amount of $3.77 thousand as of 2025-06-30, per its S-1 filed 2026-07-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2026-07-17
- PROPANC BIOPHARMA, INC. debt conversion, original debt, amount for the quarter ending 2014-09-30 was -$2.50K.
- PROPANC BIOPHARMA, INC. debt conversion, original debt, amount for the quarter ending 2013-12-31 was $0.00.
- PROPANC BIOPHARMA, INC. debt conversion, original debt, amount for the quarter ending 2013-09-30 was $0.00.
- PROPANC BIOPHARMA, INC. debt conversion, original debt, amount for the quarter ending 2013-03-31 was $0.00.
| Period end | Debt Conversion, Original Debt, Amount | Debt Conversion, Original Debt, Amount 0 month | Debt Conversion, Original Debt, Amount 1 month | Debt Conversion, Original Debt, Amount 3 month | Debt Conversion, Original Debt, Amount 6 month | Debt Conversion, Original Debt, Amount 9 month | Debt Conversion, Original Debt, Amount 12 month | Debt Conversion, Original Debt, Amount 51 month | Debt Conversion, Original Debt, Amount 54 month | Debt Conversion, Original Debt, Amount 57 month | Debt Conversion, Original Debt, Amount 60 month | Debt Conversion, Original Debt, Amount 63 month | Debt Conversion, Original Debt, Amount 66 month | Debt Conversion, Original Debt, Amount 68 month | Debt Conversion, Original Debt, Amount 72 month | Debt Conversion, Original Debt, Amount 75 month | Debt Conversion, Original Debt, Amount 77 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $3.77K S-1 · filed 2026-07-17 | ||||||||||||||||
| 2014-12-10 | $7.37K 10-K · filed 2016-09-28 | ||||||||||||||||
| 2014-12-09 | $5.36K 10-K · filed 2016-09-28 | ||||||||||||||||
| 2014-09-30 | -$2.50K 10-Q · filed 2014-11-19 | ||||||||||||||||
| 2014-07-18 | $50.00K 10-K · filed 2016-09-28 | ||||||||||||||||
| 2014-03-31 | $341.21K 10-Q · filed 2014-05-20 | ||||||||||||||||
| 2013-12-31 | $0.00 derived: 10-Q 75 month − 10-Q 72 month · filed 2014-02-14 | $0.00 derived: sum of 2 quarters · filed 2014-11-19 | $341.21K 10-Q · filed 2014-02-14 | ||||||||||||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-19 | $341.21K 10-Q · filed 2013-11-14 | |||||||||||||||
| 2013-06-30 | $341.21K 10-K · filed 2013-10-15 | ||||||||||||||||
| 2013-03-31 | $0.00 derived: 10-Q 66 month − 10-Q 63 month · filed 2013-05-20 | $0.00 derived: sum of 2 quarters · filed 2013-05-20 | $0.00 derived: sum of 3 quarters · filed 2013-05-20 | $0.00 derived: sum of 4 quarters · filed 2013-05-20 | $341.21K 10-Q · filed 2013-05-20 | ||||||||||||
| 2012-12-31 | $0.00 derived: 10-Q 63 month − 10-Q 60 month · filed 2013-02-20 | $0.00 derived: sum of 2 quarters · filed 2013-02-20 | $0.00 derived: sum of 3 quarters · filed 2013-02-20 | $0.00 derived: sum of 4 quarters · filed 2013-02-20 | $341.21K 10-Q · filed 2013-02-20 | ||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 60 month − 10-K 57 month · filed 2012-11-19 | $0.00 derived: sum of 2 quarters · filed 2012-11-19 | $0.00 derived: sum of 3 quarters · filed 2012-11-19 | $341.21K 10-Q · filed 2012-11-19 | |||||||||||||
| 2012-06-30 | $0.00 derived: 10-K 57 month − 10-Q 54 month · filed 2012-10-15 | $0.00 derived: sum of 2 quarters · filed 2012-10-15 | $341.21K 10-K · filed 2012-10-15 | ||||||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 54 month − 10-Q/A 51 month · filed 2012-05-21 | $341.21K 10-Q · filed 2012-05-21 | |||||||||||||||
| 2011-12-31 | $0.00 10-Q/A · filed 2012-03-07 | $341.21K 10-Q/A · filed 2012-03-07 | |||||||||||||||
| 2010-12-31 | $0.00 10-Q/A · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |